Publications

Authors:

Gisondi, Paolo; Bellinato, Francesco; Galeone, Carlotta; Turati, Federica; Idolazzi, Luca; Zabotti, Alen; Mcgonagle, Dennis; Girolomoni, Giampiero

Title:

Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics

Year:

2025

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

Annals of the Rheumatic Diseases

ISSN of journal:

0003-4967

Page numbers:

435-441

Keyword:

the risk of psoriatic arthritis (PsA) in plaque psoriasis (PsO) patients

Short description of contents:

Objectives: To investigate the risk of psoriatic arthritis (PsA) in plaque psoriasis (PsO) patients receiving different classes of biologics. Methods: A retrospective observational study involving consecutive bionaïve PsO patients starting biologic treatment was performed. We compared the occurrence of PsA by the class of the biologic (tumour necrosis factor [TNF], interleukin [IL]-17, or IL-23 inhibitors) using inverse probability of treatment weighting (IPTW) in the setting of multiple treatments to balance pretreatment covariates across cohorts and thus adjust for potential confounders. An IPTW Cox regression model was used to estimate hazard ratios (HRs) of PsA for IL-17 and IL-23 inhibitors versus TNF inhibitors. Results: In total, 622 patients, 430 (62.4%) males, mean ± SD age 46.9 ± 12.9 years, were included. They have been treated with TNF (n = 317, 50.9%), IL-17 (n = 164, 26.4%) or IL-23 inhibitors (n = 141, 22.7%) and followed for 2510 person-years (a mean of 4.1 ± 2.1 years per person). TNF, IL-17, and IL-23 inhibitor cohorts had a total of 1569, 486, and 455 person-years of follow-up. A total of 60 (10%) out of 622 patients on biologic therapy developed incident PsA during the observation period: 45 (14.2%) in the TNF, 9 (5.5%) in the IL-17, and 6 (4.3%) in the IL-23 inhibitor cohorts. After IPTW, the 3 treatment cohorts were well-balanced, and the HRs of PsA were 0.63 (95% CI, 0.38-1.05) for IL-17 and 0.57 (95% CI, 0.34-0.96) for IL-23 compared with the TNF treatment group. Conclusions: The risk o

Product ID:

144733

Handle IRIS:

11562/1157628

Last Modified:

March 19, 2025

Bibliographic citation:

Gisondi, Paolo; Bellinato, Francesco; Galeone, Carlotta; Turati, Federica; Idolazzi, Luca; Zabotti, Alen; Mcgonagle, Dennis; Girolomoni, Giampiero, Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics «Annals of the Rheumatic Diseases» , 2025 , pp. 435-441

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo